

Hisato Kawakami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3966288/publications.pdf>

Version: 2024-02-01

109
papers

3,488
citations

201674

27
h-index

149698

56
g-index

111
all docs

111
docs citations

111
times ranked

5012
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2419-2430. | 27.0 | 681 |
| 2 | Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 30. | 3.0 | 309 |
| 3 | Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789. | 10.7 | 234 |
| 4 | Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864. | 30.7 | 209 |
| 5 | Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 529-536. | 2.6 | 128 |
| 6 | Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection. <i>PLoS ONE</i> , 2014, 9, e101902. | 2.5 | 106 |
| 7 | Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 651-658. | 4.4 | 99 |
| 8 | Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 378-389. | 3.4 | 99 |
| 9 | Targeting MET Amplification as a New Oncogenic Driver. <i>Cancers</i> , 2014, 6, 1540-1552. | 3.7 | 96 |
| 10 | <i>HER2</i> amplification as a potential therapeutic target in gastric cancer. <i>Oncotarget</i> , 2013, 4, 9-17. | 1.8 | 82 |
| 11 | An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. <i>Oncogene</i> , 2019, 38, 1398-1409. | 5.9 | 69 |
| 12 | [Fam] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification. <i>International Journal of Cancer</i> , 2019, 145, 3414-3424. | 5.1 | 62 |
| 13 | The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. <i>Oncotarget</i> , 2014, 5, 11847-11856. | 1.8 | 61 |
| 14 | Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 347-354. | 2.6 | 57 |
| 15 | Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. <i>Cancer Medicine</i> , 2019, 8, 1258-1268. | 2.8 | 54 |
| 16 | Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. <i>Cancers</i> , 2020, 12, 400. | 3.7 | 50 |
| 17 | Implications of mismatch repair-deficient status on management of early stage colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 676-84. | 1.4 | 49 |
| 18 | Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. <i>European Journal of Cancer</i> , 2020, 129, 97-106. | 2.8 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2021, 26, e588-e596. | 3.7 | 48 |
| 20 | A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4000-4000. | 1.6 | 48 |
| 21 | The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. <i>Journal of Biological Chemistry</i> , 2015, 290, 23838-23849. | 3.4 | 46 |
| 22 | U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. <i>Journal of Clinical Investigation</i> , 2019, 130, 374-388. | 8.2 | 43 |
| 23 | KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 5697-5707. | 7.0 | 42 |
| 24 | MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. <i>Gastric Cancer</i> , 2016, 19, 687-695. | 5.3 | 37 |
| 25 | Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. <i>British Journal of Cancer</i> , 2021, 124, 914-924. | 6.4 | 37 |
| 26 | Mutant <i>BRAF</i> Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 3015-3027. | 4.1 | 36 |
| 27 | HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 390-403. | 7.0 | 34 |
| 28 | Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 52-60. | 3.9 | 31 |
| 29 | Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). <i>Esophagus</i> , 2021, 18, 90-99. | 1.9 | 30 |
| 30 | Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 1-25. | 2.6 | 29 |
| 31 | Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma. <i>Cancer Medicine</i> , 2013, 2, 933-941. | 2.8 | 27 |
| 32 | Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251. | | 26 |
| 33 | HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016, 11, 267-274. | 1.6 | 25 |
| 34 | Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. <i>Molecular Cancer Research</i> , 2015, 13, 659-669. | 3.4 | 22 |
| 35 | T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2563-2571. | 4.1 | 19 |
| 36 | Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. <i>Oncotarget</i> , 2016, 7, 84860-84871. | 1.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. <i>Investigational New Drugs</i> , 2018, 36, 726-731. | 2.6 | 17 |
| 38 | Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e239-e241. | 1.1 | 17 |
| 39 | Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).. <i>Journal of Clinical Oncology</i> , 2021, 39, 161-161. | 1.6 | 17 |
| 40 | Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. <i>Molecular Oncology</i> , 2022, 16, 1493-1507. | 4.6 | 17 |
| 41 | Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08). <i>Gastric Cancer</i> , 2022, 25, 235-244. | 5.3 | 17 |
| 42 | Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. <i>European Journal of Cancer</i> , 2013, 49, 3003-3009. | 2.8 | 16 |
| 43 | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3505-3505. | 1.6 | 16 |
| 44 | Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGS1105, HERBIS-4A Trial. <i>Oncologist</i> , 2018, 23, 1411-e147. | 3.7 | 15 |
| 45 | Human Epidermal Growth Factor Eyedrops for Cetuximab-Related Filamentary Keratitis. <i>Journal of Clinical Oncology</i> , 2011, 29, e678-e679. | 1.6 | 14 |
| 46 | Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. <i>Cancer Science</i> , 2013, 104, 98-104. | 3.9 | 14 |
| 47 | Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGS1602. <i>Oncologist</i> , 2021, 26, 17-e47. | 3.7 | 13 |
| 48 | A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. <i>Scientific Reports</i> , 2019, 9, 11340. | 3.3 | 12 |
| 49 | Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. <i>Oncogenesis</i> , 2019, 8, 54. | 4.9 | 12 |
| 50 | An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT). <i>TJ</i> 2020, 10, 10-17. | 3.7 | 10 |
| 51 | Folate receptor 1 increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAB-02 in gastric cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e454. | 4.0 | 11 |
| 52 | Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer. <i>Investigational New Drugs</i> , 2014, 32, 946-954. | 2.6 | 10 |
| 53 | Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. <i>Oncologist</i> , 2019, 24, 163. | 3.7 | 10 |
| 54 | A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical Stage III/IV Gastric Cancer (OGS1601). <i>Oncologist</i> , 2020, 25, 119. | 3.7 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Phase III study of pembrolizumab combined with S-1 oxaliplatin or S-1 cisplatin as first-line chemotherapy for gastric cancer. <i>Cancer Science</i> , 2022, 113, 2814-2827. | 3.9 | 10 |
| 56 | Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 1921-1929. | 1.3 | 9 |
| 57 | Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: A multicenter, open-label, single-arm, prospective phase II study (OGSG1108). <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 776-784. | 2.4 | 9 |
| 58 | Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. <i>Oncotarget</i> , 2017, 8, 80286-80294. | 1.8 | 9 |
| 59 | FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 314-322. | 3.9 | 8 |
| 60 | Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. <i>Esophagus</i> , 2022, 19, 137-145. | 1.9 | 8 |
| 61 | DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer. <i>Future Oncology</i> , 2019, 15, 2441-2447. | 2.4 | 7 |
| 62 | Comparison of S-1 cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1635-1643. | 2.2 | 7 |
| 63 | Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3). <i>Gastric Cancer</i> , 2021, 24, 428-434. | 5.3 | 7 |
| 64 | Serum lactate dehydrogenase is a predictive biomarker in patients with oropharyngeal cancer undergoing radiotherapy: Retrospective study on predictive factors. <i>Head and Neck</i> , 2021, 43, 3132-3141. | 2.0 | 7 |
| 65 | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01). <i>Journal of Clinical Oncology</i> , 2020, 38, 4513-4513. | 1.6 | 7 |
| 66 | REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. <i>Future Oncology</i> , 2021, 17, 869-875. | 2.4 | 6 |
| 67 | A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). <i>International Journal of Clinical Oncology</i> , 2020, 25, 2035-2043. | 2.2 | 5 |
| 68 | Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802). <i>International Journal of Clinical Oncology</i> , 2020, 25, 1291-1298. | 2.2 | 5 |
| 69 | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-242. | 1.6 | 5 |
| 70 | Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 279-285. | 2.3 | 4 |
| 71 | Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. <i>European Journal of Cancer</i> , 2021, 154, 307-315. | 2.8 | 4 |
| 72 | Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). <i>Journal of Clinical Oncology</i> , 2018, 36, 670-670. | 1.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Two-step Intensity-modulated Radiation Therapy for Oropharyngeal Cancer: Initial Clinical Experience and Validation of Clinical Staging. <i>Anticancer Research</i> , 2018, 38, 979-986. | 1.1 | 4 |
| 74 | Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 322-322. | 1.6 | 3 |
| 75 | Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, v231-v232. | 1.2 | 2 |
| 76 | Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 4050. | 2.4 | 2 |
| 77 | The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19082-e19082. | 1.6 | 2 |
| 78 | Pharmacokinetics (PK) and Safety of Teseaxel, a Novel Oral Taxane, in Japanese Patients (PTS) with Advanced Solid Tumors. <i>Annals of Oncology</i> , 2012, 23, ix167. | 1.2 | 1 |
| 79 | A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood. <i>Case Reports in Oncology</i> , 2020, 13, 843-848. | 0.7 | 1 |
| 80 | Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1871-1880. | 2.2 | 1 |
| 81 | Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120. | 1.6 | 1 |
| 82 | Abstract 2937: MEK/ERK inhibitor GDC-0623 dephosphorylates and accumulates BIM that enables a synergistic apoptosis with the Bcl-xL antagonist, ABT-263, in mutantKRAScolorectal cancer cells. , 2015, , . | | 1 |
| 83 | Abstract 2173: Targeting CDK1 and MEK/ERK overcome mutantBRAF-mediated apoptosis resistance in human colorectal cancer cells. , 2017, , . | | 1 |
| 84 | Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 624-624. | 1.6 | 1 |
| 85 | Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15106-e15106. | 1.6 | 1 |
| 86 | Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.. <i>Journal of Clinical Oncology</i> , 2019, 37, 578-578. | 1.6 | 1 |
| 87 | OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 251-e304. | 3.7 | 1 |
| 88 | Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus Sâ€™â€™ therapy. <i>BMC Cancer</i> , 2022, 22, . | 2.6 | 1 |
| 89 | Heregulin as a Biomarker for Anti-Her3 Antibody Patritumab Combined with Erlotinib in Non-Small Cell Lung Cancer. <i>Annals of Oncology</i> , 2014, 25, v73. | 1.2 | 0 |
| 90 | Clinical Benefit of Continued Therapy with Crizotinib Beyond Initial Disease Progression in Advanced Alk Positive Nscl. <i>Annals of Oncology</i> , 2014, 25, v70. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | 49 Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Bcl-xL Antagonism and Induction of Pro-Apoptotic BH3-Only Proteins in Colorectal Carcinoma Cells. <i>Gastroenterology</i> , 2015, 148, S-15. | 1.3 | 0 |
| 92 | Sa1808 Mutant BRAF (V600E) Phosphorylates MCL-1 to Increase Stability/Expression That Confers Apoptosis Resistance in Colorectal Cancer Cells. <i>Gastroenterology</i> , 2016, 150, S372. | 1.3 | 0 |
| 93 | A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601).. <i>Journal of Clinical Oncology</i> , 2021, 39, 203-203. | 1.6 | 0 |
| 94 | Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer: OGSG 1602, survival update data.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3558-3558. | 1.6 | 0 |
| 95 | Randomized phase II study comparing docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma who are refractory to fluoropyrimidine and platinum-based chemotherapy: OGSG1201.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4037-4037. | 1.6 | 0 |
| 96 | Abstract 4657: MET amplification as a potential therapeutic target in gastric cancer.. , 2013, , . | | 0 |
| 97 | Phase I dose finding study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, alone or in combination with paclitaxel in Japanese patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13501-e13501. | 1.6 | 0 |
| 98 | Abstract 1844: Novel HER3 neutralizing antibody, patritumab abrogates cetuximab resistance mediated by a heregulin-autocrine loop in colorectal cancer. , 2014, , . | | 0 |
| 99 | Abstract 2939: Heregulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vivo. , 2016, , . | | 0 |
| 100 | Abstract 2115: MEK/ERK and MCL-1 inhibition synergistically reverse apoptosis resistance in colon cancer cells with BRAF(V600E)-mediated MCL-1-upregulation. , 2016, , . | | 0 |
| 101 | Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 603-603. | 1.6 | 0 |
| 102 | Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102. | 1.6 | 0 |
| 103 | The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS885-TPS885. | 1.6 | 0 |
| 104 | Abstract 2336: Targeting CDK1 and MEK/ERK overcomes apoptosis resistance in BRAFV600E human colorectal cancer cells. , 2018, , . | | 0 |
| 105 | REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progressive disease of nivolumab (NIV) therapy for metastatic gastric cancer (mGC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS178-TPS178. | 1.6 | 0 |
| 106 | A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (OGSG 1106).. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-144. | 1.6 | 0 |
| 107 | Abstract 1668: A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. , 2019, , . | | 0 |
| 108 | Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4071-4071. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer: A Phase II Study (OGSG 1107). <i>Gastrointestinal Tumors</i> , 2022, 9, 27-36. | 0.7 | 0 |